HOT TAKES | FDA Proposes Mandatory GRAS Notification Program—What You Need to Know Now

On August 10, 2026, FDA released a pre-publication version of a proposed rule that would convert the current voluntary GRAS notification program into a mandatory program for both human and animal food substances. The proposed rule is scheduled for Federal Register publication on August 11, 2026, as Docket No. FDA-2025-N-3262 (RIN 0910-AJ02). A detailed client alert analyzing the proposal will follow within 24 hours.

Ten Things You Need to Know

1. Voluntary becomes mandatory. Any person introducing a substance into interstate commerce under the GRAS provision of section 201(s) of the FD&C Act would be required to notify FDA of the basis for their GRAS conclusion. This applies to substances already in the food supply and new introductions alike.
2. This is not premarket approval. FDA expressly states that companies may continue marketing GRAS substances before submitting a notice, after submission, and during FDA review—provided the use actually satisfies the statutory GRAS criteria. The proposal is framed as a post-market information-gathering tool.
3. The consequence of non-notification is soft—but real. FDA would treat failure to notify as a factor in prioritizing substances for post-market review. Non-notification alone would not constitute a per se adulteration finding or an FDA determination that a use is not GRAS.
4. Seven exceptions for human food. Proposed exceptions include uses covered by an existing "no questions" letter, substances listed or affirmed as GRAS in FDA regulations, certain historical-use substances, uses reviewed through established FDA consultation processes (e.g., biotechnology, cultured animal cells), threshold-of-regulation exemptions, and uses covered by an effective food-contact notification.
5. A streamlined pathway exists for substances already on the market. For substances in interstate commerce before the final rule's effective date based on independent GRAS conclusions, FDA proposes a time-limited streamlined submission requiring only identifying information—not the underlying safety data. The window would be open for one year after the effective date. But this is a conditional deferral, not a permanent exemption: FDA retains discretion to later require a full GRAS notice or food additive petition.
6. Your "no questions" letters may not be as secure as you think. FDA proposes authority to revisit, update, or rescind prior "no questions" letters if new information calls the GRAS conclusion into question. Companies that have treated these letters as de facto regulatory clearance should reassess.
7. Confidentiality is use-it-or-lose-it. Under the proposal, any data or information not specifically identified as exempt from FOIA at the time of submission may be treated as nonexempt or subject to a waiver of confidentiality. Failure to designate at the time of filing could result in irreversible public disclosure.
8. The comment period is 120 days. Comments are due approximately December 9, 2026 (120 days from the August 11 publication date). FDA also invites comments through the Paperwork Reduction Act process on burden estimates.
9. The timeline to compliance is measured in years, not months. If finalized, the mandatory notification provisions would have a compliance date of 18 months after the effective date, which itself would be 60 days after publication of the final rule. The streamlined submission window would close one year after the effective date.
10. The political commitment behind this is significant. The rulemaking was initiated at the direction of HHS Secretary Robert F. Kennedy Jr. as part of the "Make America Healthy Again" initiative, suggesting institutional momentum toward finalization.

What to Do Right Now

• Inventory all GRAS uses currently marketed on the basis of independent GRAS conclusions and identify which proposed exceptions may apply
• Preserve evidence documenting when each independently concluded GRAS use entered interstate commerce—this is critical for the streamlined submission pathway
• Review existing GRAS dossiers for completeness and assess whether "no questions" letters cover current conditions of use, including any changes in manufacturing or specifications
• Evaluate confidentiality implications and ensure procedures are in place to designate trade secrets and CBI at the time of submission
• Begin marshaling data to support public comments, particularly regarding actual preparation costs, FDA review capacity, and the practical utility of the proposed information collection

We are conducting a comprehensive analysis of the 140-page proposed rule and will circulate a detailed client alert within 24 hours. In the meantime, please contact any of the authors listed above if you have immediate questions about how the proposal may affect your organization.